ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator

PALO ALTO, Calif., May 23, 2018 -- (Healthcare Sales & Marketing Network) -- ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypert... Devices, Cardiology ReCor Medical, Paradise System, hypertension, Renal Denervation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news